Decoy Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Broadway Ste 14, Cambridge, Massachuse...Phone Number
(713) 913-5608Website
www.decoytx.comRevenue
-Stock Symbol
DCOYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Decoy Therapeutics
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.Explore more
Decoy Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Decoy Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Decoy Therapeutics
Product Launch: Get notified when Decoy Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Decoy Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Decoy Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Decoy Therapeutics has new funding data
Check if Decoy Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Decoy Therapeutics recently announced quarterly report
Check out if Decoy Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Decoy Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Decoy Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Decoy Therapeutics.
Decoy Therapeutics financials insights
Gather financial insights about Decoy Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$1.2M
2026
Stock/Share Issuance
$3.5M
Decoy Therapeutics Tech Stack
A closer look at the technologies used by Decoy Therapeutics
Most Recent Scoops
Person-Based
Person-Based
Medical Research
Person-Based
Person-Based
Governance
Funding
Funding
Decoy Therapeutics News & Media
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families,...Today’s Best Stocks to Watch: Weight-Loss Wars, Biotech and Critical Minerals
The spotlight is heating up across four very different high-catalyst stories: $VKTX, $NTHI, $DCOY, and $GRMLDecoy Therapeutics Exploring Pan-Filovirus Program via FDA Animal Rule Pathway and Non-Dilutive Funding
Next-Generation D-MAVs™ Demonstrate Potent In Vitro Activity Against Ebola Zaire and Marburg Viruses; Targeting High-Value FDA Priority Review Voucher Eligibility CAMBRIDGE, Mass., Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering...Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Decoy Therapeutics
Sign Up For FreeTo access detailed company insights
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and... Read More
